Earlier Menopause and Risk of Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Global Cohort Study
Open Access
- 10 January 2026
- journal article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 42 (1) , e70121
Abstract
Objectives: Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a growing public health concern that contributes to liver and cardiovascular complications. The prevalence of MASLD in women increases sharply around age 50 years, but the relationship between an earlier age at natural menopause and MASLD is unknown. Methods: Using the TriNetX global federated network, we identified women with earlier menopause (< 50 years). The control cohort consisted of similarly aged pre‐menopausal women. Cases of premature (< 40 years) or surgical menopause, non‐MASLD causes of steatotic liver disease (SLD), or sex‐hormone therapy were excluded. Propensity‐score matching adjusted for baseline characteristics and metabolic risk factors, resulting in two matched cohorts of 20,979 women (total n = 41,958) in the final analysis. Outcomes included new diagnoses of MASLD (metabolic dysfunction‐associated steatohepatitis) and the MASLD metabolic factors: pre‐diabetes/diabetes, hypertension, dyslipidaemia, and overweight/obesity over 5 years of follow‐up. Results: Earlier menopause was associated with an increased risk of developing MASLD (HR 1.322, 95% CI 1.170–1.492), new‐onset dyslipidaemia (1.083; 1.045–1.122) and pre‐diabetes (1.130; 1.060–1.205). Findings were consistent across stratified analyses by pre‐existing metabolic risk factors (HR 95% CI for MASLD with pre‐existing dysglycaemia 1.370, 1.042–1.800; dyslipidaemia 1.340, 1.053–1.705; hypertension 1.230, 0.998–1.516; overweight 1.280, 1.086–1.510). Conclusions: Risk of MASLD is increased following menopause before age 50. Further studies should assess the incorporation of menopause timing into female‐specific cardiometabolic risk assessment.Keywords
Funding Information
- Hadassah Medical Organization
- Israel Science Foundation (2139/21)
This publication has 41 references indexed in Scilit:
- Sensitivity Analysis in Observational Research: Introducing the E-ValueAnnals of Internal Medicine, 2017
- Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic SteatohepatitisClinical Gastroenterology and Hepatology, 2017
- A Harmonized Data Quality Assessment Terminology and Framework for the Secondary Use of Electronic Health Record DataeGEMs (Generating Evidence & Methods to improve patient outcomes), 2016
- A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver diseaseHepatology, 2016
- Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosisDisease Models & Mechanisms, 2015
- The influence of menopause on the development of hepatic fibrosis in nonobese women with nonalcoholic fatty liver diseaseHepatology, 2014
- Factors Related to Age at Natural Menopause: Longitudinal Analyses From SWANAmerican Journal of Epidemiology, 2013
- Type II diabetes mellitus and menopause: a multinational studyClimacteric, 2013
- Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo‐controlled trialClinical Endocrinology, 2006
- Serum follicle-stimulating hormone and luteinizing hormone levels in women aged 35-60 in the U.S. population: the Third National Health and Nutrition Examination Survey (NHANES III, 1988-1994).1999